Inspire Medical Systems, Inc. (NYSE: INSP) is currently embroiled in a proposed class-action lawsuit that accuses the company of misleading investors about the readiness and market demand for its much-anticipated sleep apnea device, the Inspire V. The lawsuit, initiated by prominent investor rights law firm Hagens Berman, highlights a stark contrast between Inspire's optimistic projections and the grim reality following the product's launch.

2. Details of the Lawsuit

The class-action suit is formally titled *City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al.*, No. 0:25-cv-04247-PJS-ECW (D. Minn.). It aims to represent investors who purchased Inspire's common stock during the class period from August 6, 2024, to August 4, 2025. The lead plaintiff deadline for the case is set for January 5, 2026.

Allegations Against Inspire Medical Systems

The complaint states that throughout the class period, Inspire consistently reassured investors that it had satisfied all regulatory, technical, and commercial requirements for the Inspire V launch. The company also communicated strong anticipated demand and touted a successful commercial rollout. However, the lawsuit claims that the reality was significantly different, as the Inspire V launch was marked by dismal initial demand.

According to the allegations, several factors contributed to the lackluster uptake of the Inspire V device:

Inventory Issues: Clinicians and healthcare providers were reportedly already stocked with older Inspire IV devices, which hampered their willingness to adopt the new Inspire V.

Training and Onboarding Delays: The suit alleges that many treatment centers failed to complete the necessary training and onboarding criteria before the launch of Inspire V. This lack of preparation further delayed the product's rollout.

Billing Complications: Although the Inspire V received approval for its CPT code for Medicare patients, required software updates for claims submissions did not take effect until July 1, 2025. This resulted in many centers opting to continue using the older Inspire IV devices for patient treatment, as they could bill for those procedures immediately.

Demand Dynamics: The complaint also suggests that demand for the Inspire V was adversely affected by customers needing to "burn down" existing inventory of Inspire IV devices, which would continue to suppress interest in the new model.

Financial Impact

The fallout from the disastrous launch was compounded when Inspire Medical Systems drastically reduced its 2025 earnings guidance by a staggering 80%, projecting earnings per share to fall between $0.40 and $0.50. This revelation led to a dramatic decline in the company's stock price, plummeting by approximately 32% or $42.04 in value the following day.

3. Hagens Berman's Response

Reed Kathrein, a partner at Hagens Berman, expressed the firm's focus on the potential misrepresentation of the product’s market readiness. He stated, “We’re focused on investors’ losses and whether Inspire may have intentionally misled investors about headwinds adversely affecting the next generation launch and the dramatic negative effect on the company’s earnings potential.”

4. Conclusion

As Inspire Medical Systems grapples with this lawsuit, investors who have suffered significant losses are encouraged to come forward to aid in the investigation. The case underscores the importance of transparency and accountability in corporate communications, particularly in the healthcare sector, where product effectiveness and market readiness can have profound impacts on both investor trust and patient care. The developments in this case will undoubtedly be closely monitored by stakeholders and the broader financial community.

Original press release